Skip to main content
SpringerLink
Log in

The Future of Anticoagulation Clinics

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Anticoagulation therapy is the foundation of treatment for thromboembolic disorders; and coumarin derivatives (warfarin in the United States) are the only orally administered anticoagulant medications currently available. Due to the expense and relative difficulties associated with this route of administration, parenteral drugs are not used routinely for long-term therapy, leaving warfarin as the anticoagulant of choice in the outpatient setting. The management of warfarin is problematic, however, due the nuances of its pharmacodynamic and pharmacokinetic profile and the requirement for frequent monitoring of blood levels.

Although management by anticoagulation clinics is considered the gold standard for warfarin therapy, management by an anticoagulation clinic may not be the optimal option from a clinician's view and, in many cases, may not be an option at all. Anticoagulation clinics may impinge on the doctor-patient relationship. Difficulties of communication and reimbursement are not ameliorated by a specialty clinic. Innovations in warfarin management, including patient self-management and computerized dosing programs, are alternatives for improved care that are available with or without input by an anticoagulation service. New oral drugs on the horizon do not require the same intensity of monitoring and do not present the same pharmacodynamic problems associated with warfarin. Warfarin will become obsolete in the foreseeable future. If anticoagulation clinics continue, they must re-define their role as the major part of the workload, warfarin management, disappears. To adapt, clinics must strengthen and enhance their role as coordinators and educators, and less so, managers of anticoagulation therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.

    Google Scholar 

  2. Bush J. Reducing risks for patients receiving warfarin. Fam Pract Manag 2002;9:35-38.

    Google Scholar 

  3. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711.

    Google Scholar 

  4. Matchar DB, Samsa GP, Cohen SJ, Oddone EZ, Jurgelski AE. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: Results of the managing anticoagulation services trial. Am J Med 2002;113:42-51.

    Google Scholar 

  5. Samsa GP, Matchar DB, Goldstein LB, et al. Quality of anticoagulation management among patients with atrial fibrillation: Results of a review of medical records from 2 communities. Arch Intern Med 2000;160:967-973.

    Google Scholar 

  6. Hirsh J, Dalen J, Anderson DR, et al. Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119:8S-21S.

    Google Scholar 

  7. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated withwarfarin. AmJMed1998;105:91-99.

    Google Scholar 

  8. Fihn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study.Warfarin Optimized Outpatient Follow-up Study Group.Ann Intern Med 1993;118:511-520.

    Google Scholar 

  9. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention. Am J Med 1993;95:315-328.

    Google Scholar 

  10. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428.

    Google Scholar 

  11. Ansell JE. Anticoagulation management clinics for the outpatient control of oral anticoagulants. Curr Opin Pulm Med 1998;4:215-219.

    Google Scholar 

  12. Ansell JE, Buttaro ML, Thomas OV, Knowlton CH. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Anticoagulation Guidelines Task Force. Ann Pharmacother 1997;31:604-615.

    Google Scholar 

  13. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647.

    Google Scholar 

  14. Caffee AE, Teichman PG. Improving anticoagulation management at the point of care. Fam Pract Manag 2002;9:35-37.

    Google Scholar 

  15. Tripodi A, Arbini AA, Chantarangkul V, Bettega D, Mannucci PM. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the international normalized ratio? Thromb Haemost 1993;70:921-924.

    Google Scholar 

  16. Gosselin RC, Owings JT, Larkin E, White RH, Hutchinson R, Branch J. Monitoring oral anticoagulant therapy with point-of-care devices: Correlations and caveats. Clin Chem 1997;43:1785-1786.

    Google Scholar 

  17. Tripodi A, Chantarangkul V, Bressi C, Mannucci PM. International sensitivity index calibration of the The Future of Anticoagulation Clinics 59 near-patient testing prothrombin time monitor, ProTime.Am J Clin Pathol 2003;119:241-245.

    Google Scholar 

  18. Tripodi A, Chantarangkul V, Mannucci P. Near-patient testing devices to monitor oral anticoagulant therapy. Br J Haematol 2001;113:847-852.

    Google Scholar 

  19. van den Besselaar AM. Accuracy, precision, and quality control for point-of-care testing of oral anticoagulation.J Thromb Thrombolysis 2001;12:35-40.

    Google Scholar 

  20. Ansell JE, Hughes R. Evolving models of warfarin management: Anticoagulation clinics, patient self-monitoring, and patient self-management.Am Heart J 1996;132:1095- 1100.

    Google Scholar 

  21. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000;133:687-695.

    Google Scholar 

  22. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995;155:2185-2189.

    Google Scholar 

  23. Hasenkam JM, Kimose HH, Knudsen L, et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur J Cardiothorac Surg 1997;11:935-942.

    Google Scholar 

  24. Lafata JE, Martin SA, Kaatz S, Ward RE. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: A cost-effectiveness analysis. J Thromb Thrombolysis 2000;9(Suppl 1):S13-S19.

    Google Scholar 

  25. Leaning KE, Ansell JE. Advances in the Monitoring of Oral Anticoagulation: Point-of-Care Testing, Patient Self-Monitoring, and Patient Self-Management. J Thromb Thrombolysis 1996;3:377-383.

    Google Scholar 

  26. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: A randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999;281:145-150.

    Google Scholar 

  27. Horstkotte D, Piper C, Wiemer M. Optimal Frequency of Patient Monitoring and Intensity of Oral Anticoagulation Therapy in Valvular Heart Disease. J Thromb Thrombolysis 1998;5(Suppl 1):19-24.

    Google Scholar 

  28. Shojania K, Duncan B, McDonald K, et al. Making Health Care Safer: A Critical Analysis of Patient Safety. Vol. AHRQ publication # 01-E058. Rockville, MD: Agency for Healthcare Research and Quality, 2001.

    Google Scholar 

  29. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost 1999;25:103-107.

    Google Scholar 

  30. Ryan PJ, Gilbert M, Rose PE. Computer control of anticoagulant dose for therapeutic management. BMJ 1989;299:1207-1209.

    Google Scholar 

  31. Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin.J Clin Pathol 1993;46:299-303.

    Google Scholar 

  32. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage.European Concerted Action on Anticoagulation. Lancet 1998;352:1505-1509.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Virginia Health System, Charlottesville, Virginia, 22908-0716, USA

    B. Gail Macik

Authors
  1. B. Gail Macik
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Macik, B.G. The Future of Anticoagulation Clinics. J Thromb Thrombolysis 16, 55–59 (2003). https://doi.org/10.1023/B:THRO.0000014594.52685.33

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:THRO.0000014594.52685.33

Search

Navigation